



(51) International Patent Classification:

C07K 16/00 (2006.01) *C12N 5/16* (2006.01)
C12N 5/00 (2006.01) *C12N 5/0781* (2010.01)
C12N 5/09 (2010.01) *G01N 33/50* (2006.01)

(21) International Application Number:

PCT/US2022/015282

(22) International Filing Date:

04 February 2022 (04.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/146,135 05 February 2021 (05.02.2021) US


(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **RICHMOND, Karen**; c/o Amgen Inc., One Amgen Center Drive, Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **KIELCZEWSKA, Agnieszka**; c/o Amgen Inc., One Amgen Center Drive, Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **OLSEN, Ole**; c/o Amgen Inc., One Amgen Center Drive, Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **HONG, Julie J.**; c/o Amgen Inc., One Amgen Center Drive, Law Dept-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: ENHANCED HYBRIDOMA GENERATION



(57) **Abstract:** Provided herein are methods of generating hybridomas and related methods of producing antigen-specific antibodies. In exemplary embodiments, the method comprises (a) preparing an enriched population of IgG-positive (IgG+) memory B cells from cells obtained from secondary lymphoid organs of one or more immunized non-human animals, wherein (i) less than or about 10% of the enriched population are IgM-positive (IgM+) B cells and/or (ii) the ratio of the IgG+ memory B cell count to IgM+ B cell count of the enriched population is greater than about 0.5, optionally, greater than about 1 or greater than about 2, (b) bulk-culturing the enriched population to obtain an expanded population; and (c) fusing cells of the expanded population with myeloma cells to obtain hybridomas. In exemplary aspects, the hybridomas obtained represent at least 10% or at least 15% of the IgG+ memory B cell repertoire produced by the immunized animals.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*